Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson’s disease

Malin von Otter1*, Sara Landgren2, Staffan Nilsson3, Dragana Celojevic1, Petra Bergström4, Anna Håkansson2, Hans Nissbrandt2, Marek Drozdzik5, Monika Bialecka5, Mateusz Kurzawski5, Kaj Blennow1, Michael Nilsson6, Ola Hammarsten4, Henrik Zetterberg1

Abstract

Background: Oxidative stress is heavily implicated in the pathogenic process of Parkinson’s disease. Varying capacity to detoxify radical oxygen species through induction of phase II antioxidant enzymes in substantia nigra may influence disease risk. Here, we hypothesize that variation in NFE2L2 and KEAP1, the genes encoding the two major regulators of the phase II response, may affect the risk of Parkinson’s disease.

Methods: The study included a Swedish discovery case-control material (165 cases and 190 controls) and a Polish replication case-control material (192 cases and 192 controls). Eight tag single nucleotide polymorphisms representing the variation in NFE2L2 and three representing the variation in KEAP1 were chosen using HapMap data and were genotyped using TaqMan Allelic Discrimination.

Results: We identified a protective NFE2L2 haplotype in both of our European case-control materials. Each haplotype allele was associated with five years later age at onset of the disease (p = 0.001) in the Swedish material, and decreased risk of PD (p = 2 × 10^-6), with an odds ratio of 0.4 (95% CI 0.3-0.6) for heterozygous and 0.2 (95% CI 0.1-0.4) for homozygous carriers, in the Polish material. The identified haplotype includes a functional promoter haplotype previously associated with high transcriptional activity. Genetic variation in KEAP1 did not show any associations.

Conclusion: These data suggest that variation in NFE2L2 modifies the Parkinson’s disease process and provide another link between oxidative stress and neurodegeneration.

Background

Oxidative stress has been implicated as a major contributing factor in neurodegenerative diseases in general and Parkinson’s disease (PD) in particular [1]. Cellular responses to oxidative stress are major determinants of disease susceptibility and aging, particularly in tissues that are sensitive to oxidative stress, such as the central nervous system [2,3]. In PD brain specimens, signs of oxidative stress are especially prominent in the substantia nigra. This may be the result of combined presence of a high dopamine metabolism generating reactive oxygen species (ROS), low levels of antioxidant glutathione and increased levels of iron catalyzing ROS formation [4]. Furthermore, genetic aberrations in oxidative responses may cause neurodegenerative diseases. Examples include mutations in SOD1 (encoding superoxide dismutase 1) that cause amyotrophic lateral sclerosis [5] and loss of function mutations in DJ-1 (encoding Parkinson disease protein 7) that leads to early onset PD with high penetrance [6].

Nuclear factor-erythroid 2 (NF-E2)-related factor 2 (Nrf2) is a member of the cap ‘n’ collar family of basic leucine zipper transcription factors that regulate the expression of many antioxidant pathway genes in the so-called phase II response [7]. Nrf2 is maintained at basal levels in cells by binding to its inhibitor protein, Kelch-like erythroid-cell-derived protein with CNC homology (ECH)-associated protein 1 (Keap1) [8,9]. Keap1 is a BTB (Broad complex, Tramtrack, Bric-a-Brac) domain-containing protein [9] that targets Nrf2
for ubiquitination by Cul3/Roc-1, leading to its constitutive degradation [10-13]. Upon exposure to oxidative stress, xenobiotics, or electrophilic metabolites of phase I enzymes, repression of Nrf2 by Keap1 ubiquitination is disrupted and newly produced Nrf2 enters the nucleus [14]. There, it forms heterodimers with other transcription regulators, such as small Maf proteins, and induces the expression of antioxidant phase II genes through interaction with the antioxidant responsive element (ARE) in the promoter of these genes [15,16]. Binding of Nrf2 to ARE drives the expression of phase II enzymes, such as NQO1 [NAD(P)H dehydrogenase (quinine) 1] and HO-1 (Heme oxygenase 1), that generate antioxidant molecules, such as glutathione [17,18].

Nrf2 has been shown to protect neurons from acute injury in culture [19-21] and in vivo [22]. Furthermore, upregulation of Nrf2 activity in astocytes delays motor neuron degeneration in a mouse model of familial amyotrophic lateral sclerosis [23].

Apart from the undisputed involvement of oxidative stress in the PD process [1] there are additional and more specific links between Nrf2 function and PD. First, nuclear localization of Nrf2 is induced in PD-affected substantia nigra, even though the response appears insufficient to protect neurons from degeneration [24]. Second, treatment of nigrostriatal cultures with Nrf2 activators protects from oxidative stress-induced loss of dopaminergic cells [25]. Third, a recently discovered function of DJ-1 is to stabilize Nrf2 by preventing its interaction with Keap1 [26]. Fourth, recent and quite striking data show that induced expression of Nrf2 in brains of transgenic mice protects from MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-caused damage to the nigrostriatal dopaminergic pathway as seen in PD [27].

Despite these extensive preclinical data, no association has as yet been demonstrated between NFE2L2 and KEAP1, the Nrf2 or Keap1 encoding genes, and neurodegenerative disease [28]. Here, we have, for the first time, performed a complete haplotype analysis of the NFE2L2 and KEAP1 genes in relation to risk of PD in two independent case-control materials. We found strong protective effects of an NFE2L2 haplotype in two independent case-control materials, indicating that varying efficiency in the oxidative protection by Nrf2 may influence PD pathogenesis.

**Methods**

**Case-control materials**

The Swedish discovery material consisted of 165 PD cases and 190 age-matched controls. All individuals were of Caucasian origin. The cases fulfilled the Parkinson’s Disease Society Brain Bank criteria for idiopathic PD [29], except for that the presence of more than one relative with PD was not considered an exclusion criterion. PD cases with an age at onset (AAO) of <50 years were screened to exclude that they were carriers of recognized PD-causing mutations in the DJ-1, Parkin, PINK1 and LRRK2 genes [30,31]. Demographic characteristics are given in table 1.

The Polish replication material consisted of 192 PD cases and 192 sex-matched controls. Controls were chosen to be of as high age as possible when included in the study to minimize the number of controls developing PD later in life. All individuals were of Caucasian origin and had no familial aggregation of PD. Demographic characteristics are given in table 1.

**Tag SNP selection**

Single nucleotide polymorphism (SNP) genotyping data covering NFE2L2 and KEAP1 for the European material CEU (Utah residents with ancestry from northern and western Europe) were downloaded from the International Haplotype Mapping Project web site http://www.hapmap.org[32] and processed in the Haploview software [33]. Linkage disequilibrium (LD) blocks were constructed according to Gabriel et al. [34] and tag SNPs were assigned using the tagger function [33]. A minor allele frequency of ≥ 5% and pair wise tagging with a minimum r2 of 0.80 were applied to capture the common variations within the blocks covering NFE2L2 and KEAP1. The common genetic variation of NFE2L2 was tagged for by eight tag SNPs: rs16865105, rs7557529, rs2886161, rs1806649, rs2001350, rs10183914, rs2706110 and rs13035806, and

| Parameter | Parkinson | Control | p-value |
|-----------|-----------|---------|---------|
| **Swedish cases and controls** | | | |
| Number of subjects | 165 | 190 | |
| Age at sampling (years) | 68.2 ± 8.8 | 69.1 ± 9.3 | 0.698 |
| Age at onset (years) | 590 ± 10.2 | — | — |
| Sex (Female) | 71 (43.0) | 120 (63.2) | <0.001 |
| (Male) | 94 (57.0) | 70 (36.8) | |
| Current smoker | 9 (8.7) | 13 (8.3) | 0.897 |
| Ever smoked | 38 (36.9) | 81 (51.6) | 0.020 |
| Parkinson’s disease in family | 40 (24.8) | 18 (9.5) | <0.001 |
| Alzheimer’s disease in family | 7 (4.3) | 8 (4.3) | 0.976 |
| **Polish cases and controls** | | | |
| Number of subjects | 192 | 192 | |
| Age at sampling (years) | 63.7 ± 10.9 | 72.9 ± 9.9 | <0.001 |
| Age at onset (years) | 552 ± 10.9 | — | — |
| Sex (Female) | 75 (39.1) | 75 (39.1) | 1.000 |
| (Male) | 117 (60.9) | 117 (60.9) | |

Data are presented as absolute numbers (%) or mean ± SD. p-values are calculated with χ2-test for categorical parameters and Mann-Whitney U test for continuous parameters.
by three tag SNPs: rs1048290, rs11085735 and rs1048287 (figure 1, table 2).

**Tag SNP genotyping**
Tag SNPs were genotyped using genomic DNA extracted from blood. TaqMan® Pre-Designed SNP genotyping assays as well as TaqMan® Custom Made SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) were used (table 2) according to the TaqMan Allelic Discrimination technology [35] on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).

**Promoter sequencing**
Promoter SNPs rs35652124, rs6706649 and rs6721961 were genotyped by sequencing. We amplified a 423 bp region of the *NFE2L2* promoter using forward primer 5'-GACCACTCTCCGACCTAAAGG-3' and reverse primer 5'-CGAGATAAAGAGTTGTTTGCGAA-3', annealing temperature 59°C and 34 cycles on a PTC-200 ThermalCycler (Biorad, Hercules, CA, USA). The product was purified using Illustra™ GFX™ PCR Purification Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Sequence reactions were performed using BigDye v3.1 (Applied Biosystems, Foster City, CA, USA) and analyzed on an ABI PRISM 3100 Automated Sequencer (Applied Biosystems, Foster City, CA, USA). All sequence data were analyzed using the DNASTAR SeqMan® software (DNASTAR Inc, Madison, WI, USA).

**Statistical Analyses**
Demographics for the PD cases and controls were compared using \( \chi^2 \)-statistics for categorical parameters, i.e. sex, family history of neurodegenerative disorders and smoking habits, and using Mann-Whitney U test for age at sampling. Effects of sex, family history of neurodegenerative disease and smoking habits were

---

**Figure 1** Schematic overview of the *NFE2L2* (panel A) and *KEAP1* (panel B) genes and the tag SNPs used in the study (for rs-numbers see table 2). Thick black lines indicate exons. The promoter region of *NFE2L2* is detailed in panel A.
analyzed by identifying significantly relevant covariates using forward stepwise logistic or linear regression in each material.

All tag SNPs were analyzed for deviation from Hardy-Weinberg equilibrium using $\chi^2$-statistics. Single marker associations were performed using logistic or linear regression in an additive model ($dd = 0$, $Dd = 1$ and $DD = 2$, where $D =$ minor allele and $d =$ major allele).

Haplotype frequencies were estimated in the HelixTree 6.3 software using the expectation-maximization algorithm [36] yielding all possible haplotypes present in our materials. In subsequent analyses, however, only haplotypes with an overall estimated frequency of >1.0% were included, while the rarer haplotypes were pooled. In the regression analysis the phase uncertainty for each individual was taken care of by coding each haplotype covariate according to the phase probabilities.

The genes were analyzed to identify the haplotype window with the strongest association to PD diagnosis and AAO of the disease, and to identify the haplotype alleles responsible for the association. To this end, we used a sliding window approach with stepwise forward logistic or linear haplotype regression including relevant covariates. The impact of each associated haplotype allele of the identified window was then investigated with logistic or linear regression including relevant covariates. Pairwise LD between the individual tag SNPs and promoter SNPs was calculated according to Gabriel et al [34] by means of $r^2$.

The p-value threshold for statistical significance used in this study was $p = 0.05$. To correct for multiple testing, Bonferroni correction for the number of studied SNPs was used in all single marker analyses and permutation tests with 10 000 permutations were performed in the sliding window model. Corrected p-values are designated as $p_c$.

The statistical softwares used were SYSTAT11 (SYSTAT Software GmbH, Erkrath, Germany) and HelixTree 6.3 (Golden Helix, Bozeman, MT, USA).

**Ethics**

The study was approved by the regional ethics committee at the University of Gothenburg, Sweden, and the ethics committee of the Pomeranian Medical University, Szczecin, Poland and was in compliance with the Helsinki Declaration of 1975. Written informed consent was obtained from all subjects.

**Results**

**Demographics**

Swedish cases and controls were well matched in age. There were significant differences in the distribution of sex, family history of PD and smoking habits (table 1). We identified sex, family history of PD and ever smoking as significantly relevant covariates for the analyses of association with disease risk. Family history of PD alone was identified as a significant covariate in analyses of association with AAO.

Polish cases and controls were matched in sex. Age at sampling was significantly higher in controls than in PD cases (table 1). No covariates were identified as significantly relevant for the analysis of association with...
disease risk. We identified sex as a significant covariate for analysis of association with AAO.

**Tag SNP genotyping**

None of the studied markers either in the Swedish or the Polish material had a Hardy-Weinberg equilibrium p-value of < 0.01. The call rate was >95% for both TaqMan genotyping and sequencing.

**Association analysis - Swedish material**

After correction for multiple testing none of the tag SNPs alone significantly affected risk of PD (table 3). The A allele of tag SNP 6 (rs10183914) in NFE2L2 was estimated to increase AAO of PD with four years per allele (p_c = 0.028). No associations were seen for the markers in KEAP1 with either risk of PD (table 3) or AAO in PD (data not shown).

The haplotype window of NFE2L2 consisting of the five consecutive tag SNPs 2-6 (rs7557529, rs2886161, rs1806649, rs2001350 and rs10183914) was strongly associated with risk of PD (p_c = 0.008), as well as with AAO of the disease (p_c = 0.003). Phasing of this window resulted in six haplotypes with a frequency of ≥ 5% in the PD group (table 4). Within this window, the haplotypes GAGGG and GAAAG were both associated with increased risk of PD, with an odds ratio of 2.4 (p = 0.007) and 3.7 (p = 0.010) per haplotype allele, respectively (table 5). Additionally, the haplotype GAAAA was estimated to increase AAO of PD with approximately five years per haplotype allele (p = 7 × 10^{-4}, table 5).

With regards to KEAPI, phasing of all three tag SNPs (rs1048290, rs11085735 and rs1048287) resulted in four haplotypes with a frequency of ≥ 5% (table 4) without significant associations with risk or AAO of the disease (data not shown).

**Promoter analysis - Swedish material**

SNPs in the NFE2L2 promoter (figure 1) have previously been shown to affect promoter activity and Nrf2 expression in vitro [37]. To test the hypothesis that the observed haplotype associations described above may be explained by linkage disequilibrium to these functional polymorphisms, we genotyped all individuals for three SNPs in the NFE2L2 promoter region by sequencing.

Phasing of the promoter window (rs35652124, rs6706649 and rs6721961) resulted in four haplotypes with a frequency of ≥ 5% (table 4). The AGA haplotype with low promoter activity [37] showed tendency association with increased risk of PD (p = 0.056, table 5) and was in LD (r^2 = 0.53) with the risk haplotype GAGGG. The protective, disease-delaying haplotype GAAAA was in LD (r^2 = 0.39) with the promoter haplotype AGC, i.e. the common promoter variant associated with full Nrf2 expression. The promoter SNPs are located between tag SNPs 2 and 3 (figure 1) and analysis of the full risk haplotype GAGAAGGG (freq: PD = 10.8%, freq controls = 4.9%) was associated with risk of PD (p = 0.002) with an odds ratio for PD of 2.8 per haplotype allele (table 5). The full protective haplotype GAGCAAAA (freq: PD = 22.5%, freq controls = 26.4%) was estimated to delay AAO in PD (p = 0.001) with approximately 5 years per haplotype allele (table 5).

**Replication of NFE2L2 associations - Polish material**

In line with the results from the Swedish material, none of the tag SNPs or promoter SNPs alone had a significant effect on the risk of PD after correction for multiple testing (table 3). The observed association of rs10183914 with AAO in the Swedish material could not be replicated (data not shown).

In line with the results from the Swedish material, the haplotype window consisting of tag SNPs 2-6 was associated with risk of PD (p = 0.005). The haplotype GAAAA of this window was associated with decreased risk of PD (p = 0.005) with an odds ratio of 0.6 (table 5). Notably, this haplotype is identical to the protective haplotype associated with delayed AAO in the Swedish material. As in the Swedish material, GAAAA was in LD (r^2 = 0.42) with the common promoter haplotype AGC. Furthermore, the AGC haplotype alone showed association with reduced risk of PD (p = 0.003) with an odds ratio of 0.6 per haplotype allele (table 5). The full protective haplotype GAGCAAAA (freq: PD = 12.6%, controls = 27.8%) showed strong association with risk of PD (p = 2 × 10^{-6}) with an odds ratio for PD of 0.4 for heterozygous carriers (table 5) and 0.2 (95% CI 0.1-0.4) for homozygous carriers. We could not replicate the risk association of the full haplotype GAGAAGGG (freq: PD = 5.9%, controls = 9.6%), since this haplotype showed association with reduced, rather than increased, risk of PD (p = 0.031) in the Polish material. There was no association with AAO in the Polish material (data not shown).

**Discussion**

To our knowledge, this is the first case-control haplotype study showing association of the Nrf2-encoding NFE2L2 gene with a neurodegenerative disease. In NFE2L2, we found a region, including the promoter, which was clearly associated with risk of PD in two independent case-control materials. A haplotype including the fully functional variant of the promoter (GAGCAAAA) was associated with delayed AAO in the Swedish material and reduced risk of PD in the Polish material. These results support each other and are in agreement with data from animal and in vitro models suggesting important protective
| SNP | rs-ID | Genotype | Swedish material | Polish material | p-value[^3] | p-value[^3] |
|-----|-------|----------|-----------------|----------------|-------------|-------------|
|     |       |          | Parkinson n = 165 | Control n = 190 | (p^-value)  | (p^-value)  |
|     |       |          | n[^1] | n[^1] |          | n[^1] | n[^1] |          |
| NFE2L2 | | | | | | | | |
| 1   | rs16865105 | GG | 9 (5.5) | 18 (9.5) | 0.720 | 10 (5.5) | 9 (4.9) | 0.716 |
|     |             | GT | 59 (36.0) | 62 (32.6) | 58 (32.0) | 65 (35.5) | |
|     |             | TT | 96 (58.5) | 110 (57.9) | 113 (62.5) | 109 (59.6) | |
| 2   | rs7557529 | AA | 39 (23.8) | 56 (29.5) | 0.782 | 60 (32.1) | 49 (27.4) | 0.043 |
|     |             | AG | 85 (51.8) | 92 (48.4) | 90 (48.1) | 75 (41.9) | (0.473) | |
|     |             | GG | 40 (24.4) | 42 (22.1) | 37 (19.8) | 55 (30.7) | |
|     | rs35652124 | GG | 15 (9.3) | 13 (7.1) | 0.564 | 26 (13.6) | 17 (9.1) | 0.053 |
|     |             | AG | 58 (35.8) | 89 (48.3) | 77 (40.3) | 67 (35.8) | |
|     |             | AA | 89 (54.9) | 82 (44.6) | 88 (46.1) | 103 (55.1) | |
| P1  | rs6706649 | AA | 4 (2.5) | 3 (1.6) | 1.000 | 6 (3.1) | 2 (1.1) | 1.000 |
|     |             | AG | 33 (20.4) | 45 (24.5) | 35 (18.3) | 42 (22.5) | |
|     |             | GG | 125 (77.1) | 136 (73.9) | 150 (78.6) | 143 (76.4) | |
| P2  | rs6721961 | AA | 1 (0.6) | 1 (0.5) | 0.056 | 6 (3.1) | 2 (1.1) | 0.833 |
|     |             | AC | 39 (24.1) | 27 (14.7) | 38 (19.9) | 43 (23.0) | |
|     |             | CC | 122 (75.3) | 156 (84.8) | 147 (77.0) | 142 (75.9) | |
| 3   | rs2886161 | GG | 16 (9.7) | 15 (7.9) | 0.578 | 27 (14.4) | 17 (9.4) | 0.0656 |
|     |             | AG | 59 (35.8) | 91 (47.9) | 75 (40.1) | 67 (37.0) | |
|     |             | AA | 90 (54.5) | 84 (44.2) | 85 (45.5) | 97 (53.6) | |
| 4   | rs1806649 | AA | 14 (8.5) | 15 (7.9) | 0.819 | 9 (4.8) | 23 (12.7) | 0.111 |
|     |             | AG | 65 (39.4) | 80 (42.1) | 60 (32.3) | 61 (33.7) | (0.121) | |
|     |             | GG | 86 (52.1) | 95 (50.0) | 117 (62.9) | 97 (53.6) | |
| 5   | rs2001350 | GG | 1 (0.6) | 0 (0.0) | 0.016 | 4 (2.1) | 0 (0.0) | 0.663 |
|     |             | AG | 35 (21.2) | 23 (12.1) | (0.224) | 28 (14.7) | 39 (20.9) | |
|     |             | AA | 129 (78.2) | 167 (87.9) | 158 (83.2) | 148 (79.1) | |
| 6   | rs10183914 | AA | 14 (8.5) | 25 (13.2) | 0.111 | 20 (10.8) | 28 (15.0) | 0.254 |
|     |             | AG | 81 (49.1) | 89 (46.8) | 73 (39.2) | 73 (39.0) | |
|     |             | AA | 90 (54.5) | 84 (44.2) | 85 (45.5) | 97 (53.6) | |
| 7   | rs2706110 | AA | 6 (3.7) | 4 (2.1) | 0.238 | 7 (4.0) | 1 (0.6) | 0.780 |
|     |             | AG | 48 (29.3) | 40 (21.1) | 45 (25.4) | 53 (30.6) | |
|     |             | GG | 110 (67.1) | 146 (76.8) | 125 (70.6) | 119 (68.8) | |
| 8   | rs13035806 | TT | 2 (1.2) | 2 (1.1) | 0.796 | 2 (1.2) | 0 (0.0) | 0.323 |
|     |             | CT | 29 (17.7) | 27 (14.2) | 28 (16.7) | 27 (14.9) | |
|     |             | CC | 133 (81.1) | 161 (84.7) | 138 (82.1) | 154 (85.1) | |
| KEAP1 | | | | | | | | |
| 1   | rs1048287 | CC | 1 (0.6) | 2 (1.1) | 0.589 | — | — | — |
|     |             | CT | 35 (21.5) | 42 (22.1) | — | — | — | |
|     |             | TT | 127 (77.9) | 146 (76.8) | — | — | — | |
| 2   | rs11085735 | TT | 2 (1.2) | 2 (1.1) | 0.737 | — | — | — |
|     |             | GT | 19 (11.7) | 24 (12.8) | — | — | — | |
|     |             | GG | 142 (87.0) | 162 (86.1) | — | — | — | |
| 3   | rs1048290 | GG | 22 (13.5) | 31 (16.3) | 0.372 | — | — | — |
|     |             | CG | 77 (47.2) | 89 (46.9) | — | — | — | |
|     |             | CC | 64 (39.3) | 70 (36.8) | — | — | — | |

Data are presented as absolute numbers (percentages). ^1For SNP locations see table 2. ^2Genotype information available for most cases as specified by the n numbers. ^3p-values were calculated using an additive logistic regression model including statistically relevant covariates.
functions of Nrf2 in the central nervous system [22,23,25], and more specifically, in the nigrostriatal dopaminergic pathway affected in PD [27].

SNPs in NFE2L2 have previously been investigated for association with PD in two data sets for which data is released to the public. The first was a Japanese multiple candidate gene study [28]. This study included three NFE2L2 SNPs: rs2886161, rs2886162 and rs2706112, which showed no evidence of single marker associations with PD. The other study was an American two tiered whole-genome association study (first: sib pair, second: case-control) [38]. This study included six NFE2L2 SNPs (rs2706110, rs10183914, rs6726395, rs34820876, rs13005431, and rs6433657) of which none were included in our study. The SNP rs6726395 showed association with PD (p = 9 × 10^{-3}) in the first tier of their study but was not replicated in the second tier (p = 0.9). This SNP is in LD (r^2 = 0.9) with rs7557529 that in our study showed association with risk of PD in the Polish material (p = 0.04), but not in the Swedish (p = 0.8).

The haplotype block identified in the Swedish discovery material consisted of five consecutive tag SNPs that are located upstream of or in intronic regions of NFE2L2. The disease-associated haplotypes could thus influence expression of Nrf2 or be linked to non-synonymous SNPs. However, SNPs that affect transcription factor function are particularly rare [39] and there are no non-synonymous SNPs with a reported frequency ≥5% within NFE2L2 either in HapMap or in the NCBI SNP database (dbSNP). In addition, the gene and protein sequences are >80% conserved across mammalian species, supporting a strong selection pressure against genetic variation in coding sequences of NFE2L2.

NFE2L2 promoter polymorphisms, on the other hand, have previously been studied and found to affect NFE2L2 promoter activity in vitro [37]. Analysis of the promoter haplotypes in our materials suggests that part of the haplotype associations with risk of PD is explained by linkage to these functional promoter SNPs. Indeed, the protective haplotype GAAAA is in linkage with the wild type, well functioning version of the promoter AGC, and the full AGC-including haplotype GAGC GAAAA was associated with decreased risk of PD in the Polish material and older AAO of PD in the Swedish material.

While an AAO-modifying gene is conceptually not the same as a risk gene they represent two overlapping concepts. An AAO-modifying gene will easily appear as a

Table 4 Haplotype frequencies in PD cases and controls

| Haplotypes\(^1\) | Swedish material | Polish material |
|------------------|------------------|-----------------|
|                  | Parkinson | Control | Parkinson | Control |
| **NFE2L2 tag SNPs 2-6** |
| AGGAG            | 26.2%     | 30.6%    | 33.9%     | 28.2%    |
| AAGAG            | 22.2%     | 22.0%    | 20.5%     | 20.5%    |
| GAAAA            | 21.5%     | 26.7%    | 18.4%     | 27.7%    |
| GAGGG            | 10.9%     | 5.5%     | 9.7%      | 9.6%     |
| GAGAA            | 10.2%     | 9.1%     | 9.9%      | 7.1%     |
| GAAGG            | 5.4%      | 1.7%     | 1.4%      | 2.5%     |
| **NFE2L2 promoter P1-P3** |
| AGC              | 47.5%     | 47.0%    | 40.8%     | 48.1%    |
| GGC              | 27.2%     | 31.2%    | 33.8%     | 27.0%    |
| AAC              | 12.6%     | 13.8%    | 12.3%     | 12.3%    |
| AGA              | 12.6%     | 7.9%     | 13.1%     | 12.6%    |
| **KEAP1 tag SNPs 1-3** |
| TGC              | 55.8%     | 52.7%    | —         | —        |
| TGG              | 26.1%     | 27.7%    | —         | —        |
| CGG              | 11.0%     | 12.0%    | —         | —        |
| TTC              | 6.7%      | 7.4%     | —         | —        |

Data are presented for haplotypes with frequencies ≥5.0% estimated with the EM-algorithm.\(^1\)For rs-numbers see table 2.

Table 5 Summary of NFE2L2 haplotypes that influence risk of PD

| NFE2L2 Haplotypes\(^3\) | Swedish material | Polish material |
|--------------------------|------------------|-----------------|
|                          | Disease Risk (OR/allele)\(^2\) | p-value\(^3\) | AAO (Years/allele) | p-value\(^3\) | Disease Risk (OR/allele)\(^2\) | p-value\(^3\) |
| **Tag SNPs 2-6** |
| GAAAA                   | 0.9 (0.6-1.3)    | 0.450           | +4.8               | 7 × 10^{-4} | 0.6 (0.4-0.9) | 0.005       |
| GAGGG                   | 2.4 (1.2-4.5)    | 0.007           | -0.1               | 0.952      | 0.9 (0.5-1.5) | 0.699       |
| GAAAG                   | 3.7 (1.3-10.6)   | 0.010           | -3.3               | 0.236      | 0.5 (0.2-1.6) | 0.239       |
| **Promoter P1-P3** |
| AGC                     | 0.9 (0.7-1.3)    | 0.538           | +2.1               | 0.061      | 0.6 (0.4-0.9) | 0.003       |
| **Full haplotypes\(^4\)** |
| GAGCAAAA                | 0.9 (0.6-1.4)    | 0.631           | +4.6               | 0.001      | 0.4 (0.3-0.6) | 2 × 10^{-6} |
| GAGAAGGG                | 2.8 (1.4-5.5)    | 0.002           | -0.3               | 0.886      | 0.5 (0.3-1.0) | 0.031       |
| GAGCAAG                | 3.3 (1.1-9.7)    | 0.028           | -2.5               | 0.387      | 0.4 (0.1-1.4) | 0.150       |

\(^1\)For rs-numbers see table 2. \(^2\)Data are given as OR (95% confidence interval). \(^3\)p values are calculated with logistic or linear regression models including the associated haplotypes and significantly relevant covariates in the specified windows. \(^4\)tag SNPs 2-6 and promoter SNPs P1-P3 in order according to chromosomal location (figure 1) with the promoter SNPs highlighted in bold.

von Otter et al. BMC Medical Genetics 2010, 11:36
http://www.biomedcentral.com/1471-2350/11/36

Page 7 of 9
risk gene in certain study designs. The two studies differ substantially in the PD patients’ AAO. The Swedish patients were on average 4 years older at disease onset compared with Polish patients. Depending on the shape of the age-dependent penetrance function for the NFE2L2 haplotypes, the Polish material may be better suited for detecting risk associations, while it may be easier to detect a genetic influence on AAO in the Swedish material.

In the Polish material the significant association was as the protective GAAA haplotype while in the Swedish the GAGGG haplotype was associated with increased risk. For obvious reasons the presence of a risk/proective haplotype implies that other haplotypes must be protective/risk haplotypes. Since the different haplotypes viewed as covariates are negative confounders (due to the constraint of a total sum of two haplotypes per individual) it is a statistical phenomenon that the regression analysis can find significance for a protective haplotype in one material, while in another material a risk haplotype is found significant.

KEAP1 showed no association with PD in the Swedish or the Polish material. This finding is consistent with the American genome-wide study discussed above in which three KEAP1 SNPs (rs11085735, rs1048287, and rs2007529) were included but did not show any association with PD [38].

Conclusions

In summary, a common NFE2L2 haplotype influences risk of PD in two discrete Caucasian case-control materials. The molecular consequence of this haplotype may be increased efficiency in the Keap1-Nrf2-ARE response to oxidative stress and thereby higher capacity to withstand endogenous or environmental risk factors for PD. Further investigations in other populations as well as functional studies addressing how the disease-associated NFE2L2 haplotype affects gene expression are now needed. To conclude, these results together with recent preclinical data provide another link between oxidative stress and the pathogenesis of PD and support NFE2L2 as a novel susceptibility gene for PD.

Acknowledgements

The authors are grateful for the excellent technical assistance of Mrs Mona Selot Palmér. This work was supported by grants from the Swedish Research Council, the Alzheimer’s Association (NIRG-08-90356), cNEUPRO, the Royal Swedish Academy of Sciences, the Sahlgrenska University Hospital, the West Sweden RUN fundings, Edith Jacobsson Foundation, Axel Linders Foundation, the Göteborg Medical Society, the Swedish Medical Society, Swedish Brain Power, Stiftelsen for Gamla Tjänarinnor, the Swedish Parkinson Foundation, Gun och Bertil Stohnes stiftelse, the Ahlén Foundation and the Alzheimer’s Foundation, Sweden. Funding sources played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Author details

1Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Blå stråket 15, 413 45 Gothenburg, Sweden. 2Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Box 431, 405 30 Gothenburg, Sweden. 3Institute of Mathematical Sciences, Department of Mathematical Statistics, Chalmers University of Technology, Chalmers tvärgata 3, 412 96 Gothenburg, Sweden. 4Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, The Sahlgrenska Academy at University of Gothenburg, Bruna stråket 16, 413 45 Gothenburg, Sweden. 5Department of Pharmacology, Pomeranian Medical University, Powstancow Wilka 72, Szczecin 70-111, Poland. 6Institute of Neuroscience and Physiology, Center for Brain Repair and Rehabilitation, The Sahlgrenska Academy at University of Gothenburg, Per Dubb slagatan 14, 413 45, Gothenburg, Sweden.

Authors’ contributions

MVO: Research project - Organization, design; Statistical analysis - Design and execution; Manuscript - Writing of first draft, review and critique. SL: Research project - Organization, design; Statistical analysis - Design and execution; Manuscript - Review and critique. SN: Statistical analysis - Design, review and critique; Manuscript - Review and critique. DC: Laboratory work - Execution, Manuscript - Review and critique. PB: Laboratory work - Execution, Manuscript - Review and critique. AH: Laboratory work - Supplier of patient material, Manuscript - Review and critique. KB: Research project - Conception, Manuscript - Review and critique. MD: Laboratory work - Supplier of patient material, Manuscript - Review and critique. MB: Laboratory work - Supplier of patient material, Manuscript - Review and critique. MK: Laboratory work - Supplier of patient material, Manuscript - Review and critique. NN: Laboratory work - Supplier of patient material, Manuscript - Review and critique. MN: Research project - Conception, Manuscript - Review and critique. OH: Research project - Conception, Manuscript - Review and critique. HZ: Research project - Conception, Manuscript - Writing of first draft, review and critique. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 29 June 2009 Accepted: 2 March 2010
Published: 2 March 2010

References

1. Zhou C, Huang Y, Przedborski S: Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008, 1147:93-104.
2. Kedar NP: Can we prevent Parkinson’s and Alzheimer’s disease? J Postgrad Med 2003, 49(3):236-245.
3. Nunomura A, Moreira PI, Lee HG, Zhu X, Castelli RJ, Smith MA, Perry G: Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Drug Targets 2007, 6(6):411-423.
4. Chinta SJ, Andersen JK: Redox imbalance in Parkinson’s disease. Biochim Biophys Acta 2008, 1780(11):1362-1367.
5. Andersen PM: Amyotrophic lateral sclerosis associated with mutations in the Cu/Zn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006, 6(1):37-46.
6. Bonifati V, Rizzu P, van Baren MJ, Schap M, Breedveld GJ, Knegel E, Dekker MC, Squitieri F, Ibanez P, Joose M, van Dongen JW, Vancanore N, van Swieten JC, Bricc A, Mezo G, van Duijn CM, Oostra BA, Heutink P: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299(5604):236-239.
7. Kessler TM, Wakabayashi N, Biswal S: Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007, 47:89-116.
8. Dhakshinamoorthy S, Jaiswal AK: Functional characterization and role of Nrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 2001, 20(29):3906-3917.
9. Ichihara K, Wakabayashi N, Kato M, Ishii T, Igarashi K, Engel JD, Yamamoto M: Keap1 represses nuclear activation of antioxidant responsive elements
by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999, 13(1):76-86.
10. Cullinan SB, Gordon JD, Jin J, Harper JW, Diehl JA: The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 2004, 24(19):8477-8486.
11. Furukawa M, Xiong Y: BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005, 25(1):161-171.
12. Kobayashi A, Kang MJ, Watai Y, Tong KI, Shibata T, Igarashi K, Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24(16):7130-7139.
13. Zhang DD, Lo SC, Cross Jv, Templeton DJ, Hannink M: Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004, 24(24):10941-10953.
14. Kobayashi A, Kang MJ, Watai Y, Tong KI, Shibata T, Uchida T, Yamamoto M: Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol 2006, 26(1):221-229.
15. Itch K, Chiba T, Takahashi S, Ishii T, Igarashi K, Kato T, Oyake T, Hayashi N, Satoh T, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2 small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochim Biophys Acta 1997, 1326(3):313-322.
16. Wild AC, MoiNova HR, Mulcahy RT: Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem 1999, 274(47):33627-33636.
17. Venugopal R, Jaiswal AK: Nrf1 and Nrf2 positively and c-Fos and Fra 1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996, 93(25):14960-14965.
18. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL: Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999, 274(37):26071-26078.
19. Vargas MR, Pehr M, Cassina P, Beckman JS, Barbeito L: Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p53NTR-dependent motor neuron apoptosis. J Neurochem 2006, 97(3):687-696.
20. Kraft AD, Johnson DA, Johnson JA: Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004, 24(5):1101-1112.
21. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH: Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003, 23(8):3394-3406.
22. Callins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA: Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 2005, 102(1):244-249.
23. Vargas MR, Johnson DA, Sarkis DW, Messing A, Johnson JA: Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008, 28(50):13574-13581.
24. Ramsey CP, Hackett CA, Monsignori PK, Rinton GP, Chia LA, Hamilton RL, Chu CT, Hargens AR, Nothnagel M, Schwenke DC, Giordano A, Tritschler H, Chin L, Kleeberger SR: Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007, 21(9):2237-2246.
25. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto M, Cho HY, Kleeberger SR: Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007, 21(9):2237-2246.
26. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PV, Frazer KA, Cox DR, Ballinger DG: High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005, 77(1):685-691.
27. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002, 30(17):3894-3900.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2350/11/36/prepub